 SHANGHAI and SAN FRANCISCO, Oct. 29, 2020 GLOBE NEWSWIRE -- Zai Lab Limited NASDAQ: ZLAB; HKEX: 9688, an innovative commercial stage biopharmaceutical company, today announced dosing of the first patient in China in the global POD1UM-101 study evaluating retifanlimab in patients with previously treated, microsatellite instability-high endometrial cancer. 